Skip to content

A randomized controlled study of the upper respiratory tract probiotic Biohalo23 as an aid to occupational health and safety (respiratory protection) for healthcare workers in China

A randomized controlled study of the upper respiratory tract probiotic Biohalo23 as an aid to occupational health and safety (respiratory protection) for healthcare workers in China

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082671
Enrollment
Unknown
Registered
2024-04-03
Start date
2024-04-19
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic respiratory diseases

Interventions

intervention group:Participants will be provided with a 30-day supply of oropharyngeal probiotics (30 lozenges) and instructed to take one lozenge per day after brushing their teeth at bedtime. Partic
control group:No oropharyngeal probiotic intervention

Sponsors

School of Medicine, Wuhan University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.HCWs (doctors, nurses and lab technicians) aged 22-65 years working full-time in a hospital, and their children aged 3-12 years who attend daycare/school and live with the HCW parent (children are optional) 2.HCW couples or their children have a history of recurrent respiratory infections (more than 3 in the previous year) 3.HCW couple or their child has a history of allergic rhinitis or asthma 4.HCW has signed written informed consent

Exclusion criteria

Exclusion criteria: 1. Immunocompromised or immunodeficient 2. Known allergy to cow's milk proteins 3. History of lower respiratory tract disease 4. History of chronic sinusitis 5. History of rheumatic diseases 6. Infectious diseases, including measles, mumps or rubella 7. Ongoing respiratory infections 8. use of antibiotics within 7 days prior to the study 9. taking other probiotic products within the last 14 days

Design outcomes

Primary

MeasureTime frame
flora on nasopharyngeal swabs;Viruses on nasopharyngeal swabs;

Countries

China

Contacts

Public ContactWang Qiang

School of Medicine, Wuhan University of Science and Technology

wangqiang@wust.edu.cn+86 159 7150 9779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026